VEGFA and vitreous hemorrhage: Bevacizumab (Avastin, Genentech Inc., San Francisco, CA), is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that is thought to induce regression of retinal neovascularization and enhance the clearance of vitreous haemorrhage.10 It has been suggested as an adjunctive therapy with laser photocoagulation and as intravitreal injection before vitrectomy to decrease the risk of early bleeding.2,11 However, the optimal timing of intravitreal bevacizumab (IVB) prior to vitrectomy is debateable.